Advisory Board, Director of Epidemiology and Real-World Evidence 

Dr Chantal Van Gils

Chantal is a seasoned specialist in real-world research, epidemiology and health economics. She brings extensive knowledge and a wealth of professional experience in harnessing population-specific analyses and quantitative methods to inform both interventional and observational clinical studies including pragmatic trials, natural history of diseases, registry-based data, patient-related outcome reports or multi-dimensional molecular medicine data.

This expertise is critical to inform development and regulatory decision-making along the value chain and product life cycles, based on integrated evidence planning.  

She provides strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy or other health authority interactions for high priority programs and/or non-interventional studies across all therapeutics areas, and notably oncology and ATMP.

Key areas of expertise
  • Real-world study design – all kinds of observational or low-interventional study designs using both primary as well as secondary data
  • Comparative effectiveness & safety analyses using real-world data as external comparator for single arm clinical trials; strategic capabilities on how to design such studies to provide compelling and acceptable evidence for regulators.
  • Health technology assessment (HTA) expert including market access and Health economics; Strategic HTA capabilities from early-stage to post-authorisation phase.
  • Oncology - >100 projects/studies within solid tumours and hemato-oncology

 

Before NDA 

Chantal worked for IQVIA (2014-2022) where she held positions as global Director of Epidemiology and also within the IQVIA NEMEA Market Access & Health Economics and Outcomes Research business unit. She led global evidence generation, market access projects and real-world evidence studies for innovative medicine projects, within oncology in particular. 

Prior to joining IQVIA she worked as Market Access manager and medical advisor at GlaxoSmithKline, predominantly in Oncology & Rare Diseases. Overall, Chantal has worked in the domain of real-world research, epidemiology and health economics for over 15 years and has 3 years of clinical experience as a medical doctor.

Chantal holds a PhD in Health Economics and a MSc in Epidemiology, Erasmus University Rotterdam, as well as a MD degree from the University of Utrecht. Her research is published in various peer-reviewed journals and she has presented at national and international conferences.

Recent Publications 

Dijkhuis S, Patel D, Foster S, van Engen A, van Gils C. The Use and Acceptability of External Comparator Studies to Support Hemato-Oncology Single-Arm Trial Submissions to Health Technology Assessment Bodies. 2022-11, ISPOR Europe 2022, Vienna, Austria. Value in Health, Volume 25, Issue 12S (December 2022)

Verbeek F, van Gils C, Heine R, Uyl-De Groot C. One Size Does Not Fit All: Calculating the Cost-Effectiveness of Multiple Indications of Pembrolizumab in the Netherlands. 2022-11, ISPOR Europe 2022, Vienna, Austria. Value in Health, Volume 25, Issue 12S (December 2022)

Arteaga Duarte CH, Fakra E, Van Gils C, Guillon P. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.

Encephale. 2019 Dec;45(6):459-467. doi: 10.1016/j.encep.2019.03.001.

Rahhali N, Chalem Y, Niemira J, van Gils CW, Blome C, Gerlier L. Validity of patient-reported outcomes from COLUMBUS, a randomized open label phase III clinical trial of encorafenib plus binimetinib versus vemurafenib in advanced BRAF-mutant melanoma. 2018-05, ISPOR 2018, Baltimore, MD, USA. Value in Health, Vol. 21, S1 (May 2018)

van Gils CW, de Groot S, Redekop WK, Koopman M, Punt CJ, Uyl-de Groot CA. Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence. Pharmacoeconomics. 2013 Aug; 31(8):703-18.

Mol L, Koopman M, van Gils CW, Ottevanger PB, Punt CJ. Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol. 2013 Jun; 52(5):950-5.

Franken MG*, van Gils CW*, Gaultney JG, Delwel GO, Goettsch W, Huijgens PC, Steenhoek A, Punt CJ, Koopman M, Redekop WK, Uyl-de Groot CA. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands. Eur J Cancer. 2013 Jan; 49(1):8-16.

van der Linden N, van Gils CW, Pescott CP, Buter J, Vergeer MR, Groot CA. Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol

 

Dr Chantal Van Gils

LinkedIn

 

Stay up to date

Contact Us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.